Literature DB >> 15083853

Elevated serum transferrin saturation and mortality.

Arch G Mainous1, James M Gill, Peter J Carek.   

Abstract

BACKGROUND: A large proportion of US adults have elevated transferrin saturation, an indicator of a predisposition for iron overload. The purpose of this study was to evaluate the relationship between elevated serum transferrin saturation and mortality.
METHODS: This cohort study was conducted using data from the First Health and Nutrition Examination Survey 1 (1971-1974) (NHANES I) merged with the NHANES I Epidemiologic Followup Study (1992) (N = 10,714). We used SUDAAN and appropriate weights to make population estimates for the adult US population (aged 25 to 74 years at baseline). All-cause mortality was evaluated in relation to serum transferrin saturation of greater than 45%, greater than 50%, greater than 55%, and greater than 60% using Cox proportional hazards regression.
RESULTS: In a Cox proportional hazards model controlling for potential confounders, including comorbid diseases, smoking, and cholesterol, all-cause mortality is significantly greater for persons with a serum transferrin saturation of more than 55%, compared with those with saturations below this cutoff (hazards ratio [HR] = 1.60, 95% confidence interval [CI], 1.17-2.21). No one who died had hemochromatosis as any of the 20 listed causes of death. Many of the underlying causes of death for persons with serum transferrin saturation levels of more than 55% are common causes of death in the general population, although these persons were more likely to have died of cirrhosis and diabetes, a finding consistent with iron overload.
CONCLUSIONS: In this nationally representative cohort of adults, those with elevated serum transferrin saturation, more than 2% of the adult US population, were at increased risk for all-cause mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083853      PMCID: PMC1466640          DOI: 10.1370/afm.25

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  26 in total

1.  Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease.

Authors:  A L Fracanzani; D Conte; M Fraquelli; E Taioli; M Mattioli; A Losco; S Fargion
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

2.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

3.  C-reactive protein and myocardial infarction.

Authors:  Pamela Sakkinen; Robert D Abbott; J David Curb; Beatriz L Rodriguez; Katsuhiko Yano; Russell P Tracy
Journal:  J Clin Epidemiol       Date:  2002-05       Impact factor: 6.437

Review 4.  Screening for hemochromatosis.

Authors:  Mark A McCullen; Darrell H G Crawford; Peter E Hickman
Journal:  Clin Chim Acta       Date:  2002-01       Impact factor: 3.786

5.  Haemochromatosis gene C282Y homozygotes in an elderly male population.

Authors:  G Willis; J Z Wimperis; K C Smith; I W Fellows; B A Jennings
Journal:  Lancet       Date:  1999-07-17       Impact factor: 79.321

6.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

Review 7.  Iron metabolism: iron deficiency and iron overload.

Authors:  N C Andrews
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

Review 8.  Hereditary hemochromatosis: a common, often unrecognized, genetic disease.

Authors:  Geraldine M McCarthy; John Crowe; Conor J McCarthy; Stephen Eustace; Dermot Kenny
Journal:  Cleve Clin J Med       Date:  2002-03       Impact factor: 2.321

9.  All-cause mortality in randomized trials of cancer screening.

Authors:  William C Black; David A Haggstrom; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2002-02-06       Impact factor: 13.506

10.  Iron overload in African Americans.

Authors:  J C Barton; C Q Edwards; L F Bertoli; T W Shroyer; S L Hudson
Journal:  Am J Med       Date:  1995-12       Impact factor: 4.965

View more
  23 in total

1.  The future of family medicine? Reflections from the front lines reveal frustration and opportunity.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

2.  Elevated transferrin saturation, health-related quality of life and telomere length.

Authors:  Arch G Mainous; Robert U Wright; Mary M Hulihan; Waleed O Twal; Christine E McLaren; Vanessa A Diaz; Gordon D McLaren; W Scott Argraves; Althea M Grant
Journal:  Biometals       Date:  2013-12-15       Impact factor: 2.949

3.  Transferrin saturation, dietary iron intake, and risk of cancer.

Authors:  Arch G Mainous; James M Gill; Charles J Everett
Journal:  Ann Fam Med       Date:  2005 Mar-Apr       Impact factor: 5.166

Review 4.  The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome.

Authors:  Arch G Mainous; Rebecca J Tanner; Mary M Hulihan; Mirna Amaya; Thomas D Coates
Journal:  Br J Haematol       Date:  2014-07-22       Impact factor: 6.998

5.  The association of biomarkers of iron status with mortality in US adults.

Authors:  A Menke; P Muntner; J M Fernández-Real; E Guallar
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-02-16       Impact factor: 4.222

Review 6.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

7.  Parameters influencing in-hospital mortality in patients hospitalized in intensive cardiac care unit: is there an influence of anemia and iron deficiency?

Authors:  Ewa Uscinska; Bozena Sobkowicz; Robert Sawicki; Izabela Kiluk; Malgorzata Baranicz; Tomasz Stepek; Milena Dabrowska; Maciej Szmitkowski; Wlodzimierz J Musial; Agnieszka M Tycinska
Journal:  Intern Emerg Med       Date:  2014-12-13       Impact factor: 3.397

8.  The mortality risk of elevated serum transferrin saturation and consumption of dietary iron.

Authors:  Arch G Mainous; Brian Wells; Peter J Carek; James M Gill; Mark E Geesey
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

9.  Transferrin saturation and hospital length of stay and mortality in Medicare beneficiaries.

Authors:  Arch G Mainous; Vanessa A Diaz; Michele E Knoll; Mary M Hulihan; Althea M Grant; Robert U Wright
Journal:  J Am Geriatr Soc       Date:  2012-12-03       Impact factor: 5.562

10.  Telomere length and elevated iron: the influence of phenotype and HFE genotype.

Authors:  Arch G Mainous; Robert U Wright; Mary M Hulihan; Waleed O Twal; Christine E McLaren; Vanessa A Diaz; Gordon D McLaren; W Scott Argraves; Althea M Grant
Journal:  Am J Hematol       Date:  2013-05-13       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.